Humanwell Healthcare (Group)Ltd Dirección

Dirección controles de criterios 2/4

El CEO de Humanwell Healthcare (Group)Ltd es Xiafei Deng, nombrado en Jun 2020, tiene una permanencia de 4.42 años. posee directamente un 0.098% de las acciones de la empresa, con un valor de CN¥35.38M. La antigüedad media del equipo directivo y de la junta directiva es de 4.6 años y 9 años, respectivamente.

Información clave

Xiafei Deng

Chief Executive Officer (CEO)

CN¥7.2m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	4.4yrs
Participación del CEO	0.1%
Permanencia media de la dirección	4.6yrs
Promedio de permanencia en la Junta Directiva	9yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Xiafei Deng (60 yo)

4.4yrs

Permanencia

CN¥7,185,300

Compensación

Mr. Xiafei Deng serves as President at Humanwell Healthcare (Group) Co.,Ltd. since June 2020. He serves as Director of Wuhan Humanwell Healthcare (Group) Co.,Ltd.and served as its Vice President until Jun...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Xiafei Deng	President & Director	4.4yrs	CN¥7.19m	0.098% CN¥ 35.4m
Yajun Wu	CFO & VP	20.7yrs	CN¥2.08m	0.059% CN¥ 21.5m
Qianlun Li	VP & Secretary	11.5yrs	CN¥1.97m	0.019% CN¥ 6.7m
Wentao Du	Vice President	21.1yrs	CN¥4.07m	0.056% CN¥ 20.2m
Lie Li	Vice President	4.6yrs	CN¥3.70m	0.032% CN¥ 11.5m
Hongjie Zhang	Vice President	no data	CN¥4.97m	0.028% CN¥ 10.1m
Qiang Yin	Vice President	4.6yrs	CN¥1.97m	0.028% CN¥ 10.1m
Qun Yu	Vice President	4.1yrs	CN¥3.69m	0.028% CN¥ 10.1m

4.6yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 600079 se considera experimentado (4.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Xiafei Deng	President & Director	25.8yrs	CN¥7.19m	0.098% CN¥ 35.4m
Min Qi	Supervisor	10.5yrs	sin datos	sin datos
Rui Zhou	Independent Director	3.5yrs	CN¥100.00k	sin datos
Lin Qing Liu	Independent director	4.5yrs	CN¥100.00k	sin datos
Xiao Dong Zhang	Director	27.8yrs	CN¥1.81m	0.029% CN¥ 10.4m
Xuehai Wang	Director	21.5yrs	CN¥618.50k	0.22% CN¥ 81.3m
Jie Li	Chairman of the Board	21.5yrs	CN¥5.67m	5.39% CN¥ 2.0b
Yue Xin Du	Chairman of the Supervisory Board	19.7yrs	CN¥66.00k	sin datos
Hansheng Zhou	Director	7.6yrs	CN¥1.81m	sin datos
Chenggang Zheng	Supervisor	4.5yrs	sin datos	sin datos
Kong Na	Representative Member of the Supervisory Board	4.5yrs	sin datos	sin datos
Xia Yuan	Employee Representative Member of the Supervisory Board	4.5yrs	sin datos	sin datos

9.0yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de 600079 se considera experimentada (9 años de antigüedad promedio).

Humanwell Healthcare (Group)Ltd Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.27 in 3Q 2023)

Upcoming dividend of CN¥0.15 per share

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment deteriorates as stock falls 16%

Second quarter 2024 earnings released: EPS: CN¥0.38 (vs CN¥0.41 in 2Q 2023)

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2024 Results on Aug 15, 2024

Dividend of CN¥0.46 announced

First quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.41 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥1.32 (vs CN¥1.54 in FY 2022)

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Investor sentiment improves as stock rises 17%

Humanwell Healthcare (Group) Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.42 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥1.54 (vs CN¥0.83 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.58 (vs CN¥0.19 in 1Q 2021)

Less than half of directors are independent

Novo Holdings A/S agreed to acquire The Ritedose Corporation from AGIC Capital, Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) and others.

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 1Q 2020)

Investor sentiment improved over the past week

New 90-day low: CN¥26.05

Investor sentiment improved over the past week

New 90-day low: CN¥27.26

New 90-day low: CN¥30.20

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥30.82

Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) entered into a preliminary letter of intent to acquire an additional 13% stake in YiChang Humanwell Pharmaceutical Co., Ltd from Li Jie, Chen Xiaoqing, and Xu Huabin.

New 90-day high - CN¥38.00

Chongqing Pharmaceutical (Group) Co., Ltd. signed the Sichuan Humanwell Pharmaceutical Co., Ltd. Equity Transfer Contract to acquire 70% stake in Sichuan Humanwell Pharmaceutical Co., Ltd from Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) for approximately CNY 360 million.

New 90-day high - CN¥36.59

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad